Interleukin-11 is the dominant Il-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically

Cancer Cell

Volumn 24, Issue 2, 2013, Pages 257-271

  Putoczki, TracyL ^a,d,g   Thiem, Stefan ^a,d,g   Loving, Andrea ^a   Busuttil, RitaA ^c,d   Wilson, NicholasJ ^b   Ziegler, PaulK ^e   Nguyen, Paul M ^a,d,g   Preaudet, Adele ^a,d,g   Farid, Ryan ^a,d,g   Edwards, Kirsten M ^b   Boglev, Yeliz ^a   Luwor, RodneyB ^d   Jarnicki, Andrew ^a,h   Horst, David ^f   Boussioutas, Alex ^c,d   Heath, JoanK ^a,d,g   Sieber, OliverM ^a,d,g   Pleines, Irina ^g   Kile, BenjaminT ^g   Nash, Andrew ^b   Greten, FlorianR ^e   McKenzie, BrentS ^b   Ernst, Matthias ^a,d,g   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b CSL LIMITED   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^h UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 6; STAT3 PROTEIN;

ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COLON CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; GENE EXPRESSION; HEMATOPOIETIC CELL; HETEROZYGOSITY LOSS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; TUMOR VOLUME;

EID: 84881534116     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.06.017     Document Type: Article

References (66)

1. Baltgalvis K.A., Berger F.G., Pena M.M., Davis J.M., Muga S.J., Carson J.A. Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 294:R393-R401.
2. Becker C., Fantini M.C., Schramm C., Lehr H.A., Wirtz S., Nikolaev A., Burg J., Strand S., Kiesslich R., Huber S., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
3. Becker C., Fantini M.C., Neurath M.F. High resolution colonoscopy in live mice. Nat. Protoc. 2006, 1:2900-2904.
4. Boerma M., Wang J., Burnett A.F., Santin A.D., Roman J.J., Hauer-Jensen M. Local administration of interleukin-11 ameliorates intestinal radiation injury in rats. Cancer Res. 2007, 67:9501-9506.
5. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
6. Boulard O., Kirchberger S., Royston D.J., Maloy K.J., Powrie F.M. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation. J.Exp. Med. 2012, 209:1309-1324.
7. Calon A., Espinet E., Palomo-Ponce S., Tauriello D.V., Iglesias M., Céspedes M.V., Sevillano M., Nadal C., Jung P., Zhang X.H., et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell 2012, 22:571-584.
8. Cantor S.B., Elting L.S., Hudson D.V., Rubenstein E.B. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003, 97:3099-3106.
9. Casanova J.L., Holland S.M., Notarangelo L.D. Inborn errors of human JAKs and STATs. Immunity 2012, 36:515-528.
10. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
11. Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut 2012, 61:918-932.
12. Deng J.Y., Sun D., Liu X.Y., Pan Y., Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J. Gastroenterol. 2010, 16:5380-5387.
13. Deutscher N., Bataille F., Hausmann M., Kiessling S., Muller-Newen G., Leeb S.N., Herfarth H., Heinrich P.C., Schölmerich J., Rogler G. Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. Int. J. Colorectal Dis. 2006, 21:573-581.
14. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18:884-901.
15. Ernst M., Najdovska M., Grail D., Lundgren-May T., Buchert M., Tye H., Matthews V.B., Armes J., Bhathal P.S., Hughes N.R., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J.Clin. Invest. 2008, 118:1727-1738.
16. Esfandi F., Mohammadzadeh Ghobadloo S., Basati G. Interleukin-6 level in patients with colorectal cancer. Cancer Lett. 2006, 244:76-78.
17. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., Travis W.D., Bornmann W., Veach D., Clarkson B., Bromberg J.F. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J.Clin. Invest. 2007, 117:3846-3856.
18. Gibson D.L., Montero M., Ropeleski M.J., Bergstrom K.S., Ma C., Ghosh S., Merkens H., Huang J., Månsson L.E., Sham H.P., et al. Interleukin-11 reduces TLR4-induced colitis in TLR2-deficient mice and restores intestinal STAT3 signaling. Gastroenterology 2010, 139:1277-1288.
19. Gounaris E., Erdman S.E., Restaino C., Gurish M.F., Friend D.S., Gounari F., Lee D.M., Zhang G., Glickman J.N., Shin K., et al. Mast cells are an essential hematopoietic component for polyp development. Proc. Natl. Acad. Sci. USA 2007, 104:19977-19982.
20. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
21. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
22. Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., Taniguchi K., Yu G.Y., Osterreicher C.H., Hung K.E., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
23. Guo Y., Nemeth J., O'Brien C., Susa M., Liu X., Zhang Z., Choy E., Mankin H., Hornicek F., Duan Z. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin. Cancer Res. 2010, 16:5759-5769.
24. Guo Y., Xu F., Lu T., Duan Z., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 2012, 38:904-910.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
27. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., Costello J.F., McCormick F., Jablons D.M. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc. Natl. Acad. Sci. USA 2003, 100:14133-14138.
28. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
29. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem. J. 1990, 265:621-636.
30. Heinrich P.C., Behrmann I., Müller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 1998, 334:297-314.
31. Jenkins B.J., Grail D., Nheu T., Najdovska M., Wang B., Waring P., Inglese M., McLoughlin R.M., Jones S.A., Topley N., et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat. Med. 2005, 11:845-852.
32. Karkera J., Steiner H., Li W., Skradski V., Moser P.L., Riethdorf S., Reddy M., Puchalski T., Safer K., Prabhakar U., et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 2011, 71:1455-1465.
33. Kim D.Y., Cha S.T., Ahn D.H., Kang H.Y., Kwon C.I., Ko K.H., Hwang S.G., Park P.W., Rim K.S., Hong S.P. STAT3 expression in gastric cancer indicates a poor prognosis. J.Gastroenterol. Hepatol. 2009, 24:646-651.
34. Lay V., Yap J., Sonderegger S., Dimitriadis E. Interleukin 11 regulates endometrial cancer cell adhesion and migration via STAT3. Int. J. Oncol. 2012, 41:759-764.
35. Lee C.G., Hartl D., Matsuura H., Dunlop F.M., Scotney P.D., Fabri L.J., Nash A.D., Chen N.Y., Tang C.Y., Chen Q., et al. Endogenous IL-11 signaling is essential in Th2- and IL-13-induced inflammation and mucus production. Am. J. Respir. Cell Mol. Biol. 2008, 39:739-746.
36. Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O., Wada K., Uchida T., Nishisaki H., Nagao M., et al. Missense mutations and a deletion of the p53 gene in human gastric cancer. Biochem. Biophys. Res. Commun. 1992, 182:215-223.
37. Matsumoto S., Hara T., Mitsuyama K., Yamamoto M., Tsuruta O., Sata M., Scheller J., Rose-John S., Kado S., Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J.Immunol. 2010, 184:1543-1551.
38. Matsuo K., Oka M., Murase K., Soda H., Isomoto H., Takeshima F., Mizuta Y., Murata I., Kohno S. Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J.Int. Med. Res. 2003, 31:69-75.
39. Morikawa T., Baba Y., Yamauchi M., Kuchiba A., Nosho K., Shima K., Tanaka N., Huttenhower C., Frank D.A., Fuchs C.S., Ogino S. STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin. Cancer Res. 2011, 17:1452-1462.
40. Moser A.R., Pitot H.C., Dove W.F. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247:322-324.
41. Musashi M., Clark S.C., Sudo T., Urdal D.L., Ogawa M. Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood 1991, 78:1448-1451.
42. Naik E., O'Reilly L.A., Asselin-Labat M.L., Merino D., Lin A., Cook M., Coultas L., Bouillet P., Adams J.M., Strasser A. Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. J.Exp. Med. 2011, 208:1351-1358.
43. Nakayama T., Yoshizaki A., Izumida S., Suehiro T., Miura S., Uemura T., Yakata Y., Shichijo K., Yamashita S., Sekin I. Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int. J. Oncol. 2007, 30:825-833.
44. Nandurkar H.H., Robb L., Tarlinton D., Barnett L., Köntgen F., Begley C.G. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood 1997, 90:2148-2159.
45. Neufert C., Becker C., Neurath M.F. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2007, 2:1998-2004.
46. Oguma K., Oshima H., Aoki M., Uchio R., Naka K., Nakamura S., Hirao A., Saya H., Taketo M.M., Oshima M. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008, 27:1671-1681.
47. Onnis B., Fer N., Rapisarda A., Perez V.S., Melillo G. Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J.Clin. Invest. 2013, 123:1615-1629.
48. Orazi A., Du X., Yang Z., Kashai M., Williams D.A. Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. 1996, 75:33-42.
49. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J.Clin. Invest. 2008, 118:560-570.
50. Puchalski T., Prabhakar U., Jiao Q., Berns B., Davis H.M. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 2010, 16:1652-1661.
51. Quesnelle K.M., Boehm A.L., Grandis J.R. STAT-mediated EGFR signaling in cancer. J. Cell. Biochem. 2007, 102:311-319.
52. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
53. Rebouissou S., Amessou M., Couchy G., Poussin K., Imbeaud S., Pilati C., Izard T., Balabaud C., Bioulac-Sage P., Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009, 457:200-204.
54. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., Williams C., Price A., Talbot I., Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
55. Santos F.P., Kantarjian H.M., Jain N., Manshouri T., Thomas D.A., Garcia-Manero G., Kennedy D., Estrov Z., Cortes J., Verstovsek S. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010, 115:1131-1136.
56. Schwitalla S., Ziegler P.K., Horst D., Becker V., Kerle I., Begus-Nahrmann Y., Lechel A., Rudolph K.L., Langer R., Slotta-Huspenina J., et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013, 23:93-106.
57. Sen M., Joyce S., Panahandeh M., Li C., Thomas S.M., Maxwell J., Wang L., Gooding W.E., Johnson D.E., Grandis J.R. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin. Cancer Res. 2012, 18:4986-4996.
58. Shin S.Y., Choi C., Lee H.G., Lim Y., Lee Y.H. Transcriptional regulation of the interleukin-11 gene by oncogenic Ras. Carcinogenesis 2012, 33:2467-2476.
59. Su L.K., Kinzler K.W., Vogelstein B., Preisinger A.C., Moser A.R., Luongo C., Gould K.A., Dove W.F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992, 256:668-670.
60. Tanaka T., Suzuki R., Kohno H., Sugie S., Takahashi M., Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005, 26:229-238.
61. Tebbutt N.C., Giraud A.S., Inglese M., Jenkins B., Waring P., Clay F.J., Malki S., Alderman B.M., Grail D., Hollande F., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 2002, 8:1089-1097.
62. Teramura M., Kobayashi S., Hoshino S., Oshimi K., Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis invitro. Blood 1992, 79:327-331.
63. Trainer D.L., Kline T., McCabe F.L., Faucette L.F., Feild J., Chaikin M., Anzano M., Rieman D., Hoffstein S., Li D.J., et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 1988, 41:287-296.
64. Tye H., Kennedy C.L., Najdovska M., McLeod L., McCormack W., Hughes N., Dev A., Sievert W., Ooi C.H., Ishikawa T.O., et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012, 22:466-478.
65. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2:541-546.
66. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.